Skip to main content
Erschienen in: World Journal of Surgery 3/2016

01.03.2016 | Original Scientific Report

Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance

verfasst von: Osamu Fukuoka, Iwao Sugitani, Aya Ebina, Kazuhisa Toda, Kazuyoshi Kawabata, Keiko Yamada

Erschienen in: World Journal of Surgery | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Prospective trials of non-surgical observation have shown progression rates of only 5–10 % in patients with asymptomatic papillary microcarcinoma (PMC). This study investigated time-dependent changes in calcification patterns and tumor vascularity on ultrasonography (US) to clarify the natural course of PMC.

Methods

We examined calcification patterns and tumor vascularity for 480 lesions in 384 patients. Calcification patterns were classified as: (A) none; (B) micro; (C) macro; or (D) rim. Tumor vascularity was classified as rich or poor via color Doppler US.

Results

After a mean of 6.8 years of observation, 29 lesions (6.0 %) had increased in size. Mean age for initial calcification pattern was 52.1 years for A (n = 135), 54.2 years for B (n = 235), 56.3 years for C (n = 96), and 60.1 years for D (n = 14), and the incidence rates of tumor enlargement were 9.6, 5.5, 3.2, and 0 %, respectively. The cumulative rate of upgrade in calcification pattern was 51.8 % at 10 years. Lesions with initially rich vascularity (n = 70) had significantly higher rate of tumor enlargement than those with poor vascularity (n = 410); however, the majority of tumor (61.4 %) with initially rich vascularity had decreased their blood supply during the follow-up. Multivariate analysis showed that strong calcification (C or D) and poor vascularity at last examination correlated significantly with non-progressive disease.

Conclusions

PMCs in older patients showed significantly stronger calcification patterns and poorer vascularity. Both consolidation of calcification and loss of vascularity occurred in a time-dependent manner during observation and were significant indicators for non-progressive disease.
Literatur
1.
Zurück zum Zitat Ebina A, Sugitani I, Fujimoto Y et al (2014) Risk-adapted management of papillary thyroid carcinoma according to our own risk-group classification system: Is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156:1579–1589CrossRefPubMed Ebina A, Sugitani I, Fujimoto Y et al (2014) Risk-adapted management of papillary thyroid carcinoma according to our own risk-group classification system: Is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156:1579–1589CrossRefPubMed
2.
Zurück zum Zitat Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164–2167CrossRefPubMed Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164–2167CrossRefPubMed
3.
Zurück zum Zitat Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 44:1222–1231. doi:10.1007/s00268-009-0359-x CrossRef Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 44:1222–1231. doi:10.​1007/​s00268-009-0359-x CrossRef
4.
Zurück zum Zitat Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387CrossRefPubMed Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387CrossRefPubMed
6.
Zurück zum Zitat Ito Y, Miyauchi A, Kihara M et al (2014) Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:27–34PubMedCentralCrossRefPubMed Ito Y, Miyauchi A, Kihara M et al (2014) Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:27–34PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Imai T, Kitano H, Sugitani I et al (2013) CQ20. When can papillary microcarcinoma (papillary carcinoma measuring 1 cm or less) be observed without immediate surgery? In: Takami H, Ito Y, Noguchi H et al (eds) Treatment of thyroid tumor: Japanese clinical guidelines. Tokyo, Springer Japan, pp 119–122CrossRef Imai T, Kitano H, Sugitani I et al (2013) CQ20. When can papillary microcarcinoma (papillary carcinoma measuring 1 cm or less) be observed without immediate surgery? In: Takami H, Ito Y, Noguchi H et al (eds) Treatment of thyroid tumor: Japanese clinical guidelines. Tokyo, Springer Japan, pp 119–122CrossRef
8.
Zurück zum Zitat Harach HR, Franssila KO, Wasenius VM (1985) Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 56:531–538CrossRefPubMed Harach HR, Franssila KO, Wasenius VM (1985) Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 56:531–538CrossRefPubMed
9.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214CrossRefPubMed Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214CrossRefPubMed
10.
Zurück zum Zitat Allo MD, Christianson W, Koivunen D (1988) Not all “occult” papillary carcinomas are “minimal”. Surgery 104:971–976PubMed Allo MD, Christianson W, Koivunen D (1988) Not all “occult” papillary carcinomas are “minimal”. Surgery 104:971–976PubMed
12.
Zurück zum Zitat Sugitani I, Yanagisawa A, Shimizu A et al (1998) Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg 22:731–737. doi:10.1007/s002689900461 CrossRefPubMed Sugitani I, Yanagisawa A, Shimizu A et al (1998) Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg 22:731–737. doi:10.​1007/​s002689900461 CrossRefPubMed
13.
Zurück zum Zitat Sugitani I, Fujimoto Y (1999) Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46:209–216CrossRefPubMed Sugitani I, Fujimoto Y (1999) Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46:209–216CrossRefPubMed
15.
Zurück zum Zitat Giordano D, Gradoni P, Oretti G et al (2010) Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol 35:118–124CrossRefPubMed Giordano D, Gradoni P, Oretti G et al (2010) Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol 35:118–124CrossRefPubMed
16.
Zurück zum Zitat Niemeier LA, Kuffner AH, Song C et al (2012) A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118:2069–2077PubMedCentralCrossRefPubMed Niemeier LA, Kuffner AH, Song C et al (2012) A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118:2069–2077PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Lin KL, Wang OC, Zhang XH et al (2010) The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294–3300CrossRefPubMed Lin KL, Wang OC, Zhang XH et al (2010) The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294–3300CrossRefPubMed
18.
Zurück zum Zitat Zheng X, Wei S, Han Y et al (2013) Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF (V600E) mutational status of 977 cases. Ann Surg Oncol 20:2266–2273CrossRefPubMed Zheng X, Wei S, Han Y et al (2013) Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF (V600E) mutational status of 977 cases. Ann Surg Oncol 20:2266–2273CrossRefPubMed
19.
Zurück zum Zitat Khoo MLC, Asa SL, Witterick IJ et al (2002) Thyroid calcification and its association with thyroid carcinoma. Head Neck 24:651–655CrossRefPubMed Khoo MLC, Asa SL, Witterick IJ et al (2002) Thyroid calcification and its association with thyroid carcinoma. Head Neck 24:651–655CrossRefPubMed
20.
Zurück zum Zitat Seiberling KA, Dutra JC, Grant T et al (2004) Role of intrathyroidal calcifications detected on ultrasound as a marker of malignancy. Laryngoscope 114:1753–1757CrossRefPubMed Seiberling KA, Dutra JC, Grant T et al (2004) Role of intrathyroidal calcifications detected on ultrasound as a marker of malignancy. Laryngoscope 114:1753–1757CrossRefPubMed
21.
Zurück zum Zitat Kim BK, Choi YS, Kwon HJ et al (2013) Relationship between patterns of calcification in thyroid nodules and histopathologic findings. Endocr J 60:155–160CrossRefPubMed Kim BK, Choi YS, Kwon HJ et al (2013) Relationship between patterns of calcification in thyroid nodules and histopathologic findings. Endocr J 60:155–160CrossRefPubMed
22.
Zurück zum Zitat Bai Y, Zhou G, Nakamura M et al (2009) Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol 22:887–894CrossRefPubMed Bai Y, Zhou G, Nakamura M et al (2009) Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol 22:887–894CrossRefPubMed
23.
Zurück zum Zitat Fukunaga FH, Yatani R (1975) Geographic pathology of occult thyroid carcinomas. Cancer 36:1095–1099CrossRefPubMed Fukunaga FH, Yatani R (1975) Geographic pathology of occult thyroid carcinomas. Cancer 36:1095–1099CrossRefPubMed
24.
Zurück zum Zitat Das DK (2009) Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor? Diagn Cytopathol 37:534–541CrossRefPubMed Das DK (2009) Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor? Diagn Cytopathol 37:534–541CrossRefPubMed
25.
Zurück zum Zitat Cappelli C, Castellano M, Braga M et al (2007) Aggressiveness and outcome of papillary thyroid carcinoma versus microcarcinoma: a mono-institutional experience. J Surg Oncol 95:555–560CrossRefPubMed Cappelli C, Castellano M, Braga M et al (2007) Aggressiveness and outcome of papillary thyroid carcinoma versus microcarcinoma: a mono-institutional experience. J Surg Oncol 95:555–560CrossRefPubMed
Metadaten
Titel
Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance
verfasst von
Osamu Fukuoka
Iwao Sugitani
Aya Ebina
Kazuhisa Toda
Kazuyoshi Kawabata
Keiko Yamada
Publikationsdatum
01.03.2016
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 3/2016
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3349-1

Weitere Artikel der Ausgabe 3/2016

World Journal of Surgery 3/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.